Can a patient be on spironolactone (25mg daily) indefinitely for acne treatment if it is effective?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Spironolactone for Long-term Acne Treatment

Spironolactone 25mg daily can be safely used indefinitely for acne treatment in women if it is effective, with long-term studies showing no serious adverse effects over periods of up to 8 years. 1, 2

Safety Profile for Long-term Use

Spironolactone has demonstrated a favorable long-term safety profile when used for acne treatment:

  • An 8-year follow-up study found no serious illnesses attributable to spironolactone after 200 person-years of exposure 1
  • No increased risk of breast, ovarian, bladder, kidney, gastric, or esophageal cancer has been observed in systematic reviews involving 4.5 million individuals 2
  • Earlier concerns about carcinogenicity based on animal studies have been disproven by large human studies, including a retrospective matched cohort study of 1.29 million women that found no association between spironolactone use and breast cancer 3

Efficacy for Acne Treatment

Spironolactone is effective for treating acne in women:

  • 66-85% of women experience significant improvement or complete clearance of acne 2
  • A recent retrospective review of 395 adult patients showed complete response in approximately two-thirds (66.1%) of patients, with 85.1% having at least a 50% improvement 4
  • The 2024 SAFA double-blinded RCT demonstrated superior outcomes with spironolactone compared to placebo, with greater differences at 24 weeks than at 12 weeks 5

Monitoring Recommendations

While 25mg is a relatively low dose (typical starting doses are 50-100mg daily), some monitoring may be appropriate:

  • For young, healthy women: Routine potassium monitoring is unnecessary 3, 2
  • For older patients or those with comorbidities: Consider potassium monitoring, especially if:
    • Patient is taking medications that affect potassium levels (ACE inhibitors, ARBs, NSAIDs, digoxin)
    • Patient has renal impairment
    • Dose is increased beyond 25mg daily 3, 2

Common Side Effects

At 25mg daily, side effects are likely to be minimal but may include:

  • Menstrual irregularities (15-30%)
  • Diuresis (29%)
  • Breast tenderness (3-5%)
  • Dizziness (3-4%)
  • Headaches (more common with spironolactone than placebo in clinical trials) 2, 5

Important Considerations and Precautions

  1. Pregnancy: Spironolactone is pregnancy category C and should be discontinued if pregnancy is planned due to potential feminization of male fetuses 2

  2. Dietary considerations: Advise patients to avoid foods high in potassium, such as low-sodium processed foods and coconut water 3

  3. Medication interactions: Avoid concurrent use with potassium supplements and monitor closely if used with ACE inhibitors, ARBs, or NSAIDs 2

  4. Contraception: Consider combined oral contraceptives for women of childbearing potential, which can help regulate menstrual cycles while on spironolactone 2

Conclusion for Clinical Practice

The 25mg daily dose is on the lower end of the typical dosing range for acne treatment, which may result in fewer side effects while still providing benefit for some patients. If the patient is responding well to this dose, continuing indefinitely appears to be safe based on current evidence. For patients who don't achieve adequate response, dose increases up to 100mg daily may be considered with appropriate monitoring.

References

Research

Long-term safety of spironolactone in acne: results of an 8-year followup study.

Journal of cutaneous medicine and surgery, 2002

Guideline

Spironolactone Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.